 |
 Video: What is a Stock Split?
|
|
|
| Cassava Sciences is a clinical-stage biotechnology company. Co. focuses on detecting and treating neurodegenerative diseases, such as Alzheimer's disease. Co.'s science is based on stabilizing, but not removing a protein in the brain. Co.'s primary product candidate, simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. Co. is conducting a Phase 3 program with simufilam in patients with mild-to-moderate Alzheimer's disease dementia. Co.'s investigational product candidate, called SavaDx, is an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. According to our Cassava Sciences stock split history records, Cassava Sciences has had 0 splits. | |
|
Cassava Sciences (SAVA) has 0 splits in our Cassava Sciences stock split history database.
Looking at the Cassava Sciences stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cassava Sciences shares, starting with a $10,000 purchase of SAVA, presented on a split-history-adjusted basis factoring in the complete Cassava Sciences stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
05/02/2014 |
|
| End date: |
04/30/2024 |
|
| Start price/share: |
$5.49 |
|
| End price/share: |
$22.15 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
303.46% |
|
| Average Annual Total Return: |
14.96% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$40,330.48 |
|
| Years: |
10.00 |
|
|
|
|
|
